WO2006117534A3 - New use - Google Patents
New use Download PDFInfo
- Publication number
- WO2006117534A3 WO2006117534A3 PCT/GB2006/001582 GB2006001582W WO2006117534A3 WO 2006117534 A3 WO2006117534 A3 WO 2006117534A3 GB 2006001582 W GB2006001582 W GB 2006001582W WO 2006117534 A3 WO2006117534 A3 WO 2006117534A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiotensin
- new use
- combination
- gluccorticosteroid
- bronchodilator
- Prior art date
Links
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000036454 renin-angiotensin system Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
New Use The invention provides medicaments comprising a combination of a HMG-CoA reductase inhibitor and a drug intervening in the renin-angiotensin system selected from angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors optionally in combination with a bronchodilator and a gluccorticosteroid in the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0508924.8A GB0508924D0 (en) | 2005-04-30 | 2005-04-30 | New use |
GB0508924.8 | 2005-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006117534A2 WO2006117534A2 (en) | 2006-11-09 |
WO2006117534A3 true WO2006117534A3 (en) | 2007-01-25 |
Family
ID=34674198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/001582 WO2006117534A2 (en) | 2005-04-30 | 2006-04-28 | New use |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0508924D0 (en) |
WO (1) | WO2006117534A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53084B (en) | 2006-07-05 | 2014-06-30 | Takeda Gmbh | Combination of hmg-coa reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-n-oxide for the treatment of inflammatory pulmonary diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0508665A2 (en) * | 1991-04-01 | 1992-10-14 | E.R. SQUIBB & SONS, INC. | Use of ACE inhibitors for lowering serum cholesterol |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US20030049314A1 (en) * | 2001-08-28 | 2003-03-13 | Liang Matthew H. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20040039033A1 (en) * | 2001-12-10 | 2004-02-26 | Atwal Karnail S. | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
US20040043991A1 (en) * | 2002-08-13 | 2004-03-04 | Picard Joseph Armand | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
US20050080087A1 (en) * | 2003-10-10 | 2005-04-14 | Annapurna Pendri | Pyrazole derivatives as cannabinoid receptor modulators |
-
2005
- 2005-04-30 GB GBGB0508924.8A patent/GB0508924D0/en not_active Ceased
-
2006
- 2006-04-28 WO PCT/GB2006/001582 patent/WO2006117534A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
EP0508665A2 (en) * | 1991-04-01 | 1992-10-14 | E.R. SQUIBB & SONS, INC. | Use of ACE inhibitors for lowering serum cholesterol |
US20030049314A1 (en) * | 2001-08-28 | 2003-03-13 | Liang Matthew H. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20040039033A1 (en) * | 2001-12-10 | 2004-02-26 | Atwal Karnail S. | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
US20040043991A1 (en) * | 2002-08-13 | 2004-03-04 | Picard Joseph Armand | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
US20050080087A1 (en) * | 2003-10-10 | 2005-04-14 | Annapurna Pendri | Pyrazole derivatives as cannabinoid receptor modulators |
Non-Patent Citations (1)
Title |
---|
CATTANEO AND REMUZZI: "Lipid oxidative stress and the anti-inflammatory properties of statins", J REN NUTR, vol. 15, no. 1, January 2005 (2005-01-01), pages 71 - 76, XP009073911 * |
Also Published As
Publication number | Publication date |
---|---|
GB0508924D0 (en) | 2005-06-08 |
WO2006117534A2 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070651L (en) | Compositions of statins with bronchodilators | |
WO2008068217A3 (en) | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system | |
IL180871A0 (en) | Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv | |
WO2007071313A3 (en) | Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases | |
WO2008043561A3 (en) | Influenza targets | |
NO20071446L (en) | Endothelin A receptor (ETA) antagonists in combination with phosphodiesterase 5 inhibitors (PDE5) and applications thereof. | |
WO2007117607A3 (en) | Quinazolines for pdk1 inhibition | |
WO2007033266A3 (en) | Dipeptidyl peptidase inhibitors for treating diabetis | |
WO2006061714A3 (en) | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis | |
IL190201A0 (en) | Pde inhibitors and combinations thereof for the treatment of urological disorders | |
TW200638950A (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
WO2006041773A3 (en) | Lactam compounds useful as protein kinase inhibitors | |
WO2003065987A3 (en) | Granzyme b inhibitors | |
MX2009008363A (en) | Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. | |
HK1103645A1 (en) | New pharmaceutical uses of the lipase inhibitor | |
UA101556C2 (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary disease | |
WO2007044325A3 (en) | Apoe4 domain interaction inhibitors and methods of use thereof | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
WO2006117761A3 (en) | Magnesium salts of hmg-coa reductase inhibitors | |
ZA200806937B (en) | Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes | |
WO2008112325A3 (en) | Treatment of autoimmune disorders | |
WO2006086609A3 (en) | Inhibitors of tryptase | |
WO2008010008A3 (en) | Cardiovascular combinations using rennin-angiotensin inhibitors | |
WO2006117534A3 (en) | New use | |
MX2010012019A (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06726962 Country of ref document: EP Kind code of ref document: A2 |